A drug that could help people who suffer from a genetic disorder that causes them to feel pain when exposed to sunlight has performed well in its Phase III crossover trial.
Scenesse was evaluated for its ability to provide preventative pharmaceutical therapy for patients with erythropoietic protoporphyria (EPP), which causes phototoxic reactions following exposure to sunlight.
Go deeper with GlobalData
The 12-month, 91-patient trial showed that patients receiving Scenesse experienced significantly lowered pain severity compared to those receiving a placebo.
The duration of exposure to sunlight and melanin levels were found to be higher following active drug treatment.
Clinuvel Pharmaceuticals, who carried out the trial, said the results demonstrate Scenesse as a systemic photoprotectant in EPP patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
